Eftrenonacog alfa

Drug Profile

Eftrenonacog alfa

Alternative Names: Alprolix; BIIB-029; Coagulation factor IX recombinant immunoglubulin G1 fusion protein; Factor IX-Fc; FIX-Fc; Recombinant factor IX Fc; rFIXFc

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Syntonix Pharmaceuticals
  • Developer Bioverativ; Swedish Orphan Biovitrum
  • Class Blood coagulation factors; Recombinant fusion proteins
  • Mechanism of Action Blood coagulation factor replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Haemophilia B
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Haemophilia B

Most Recent Events

  • 10 Jul 2017 Health Canada approved the transfer of the marketing licenses for eftrenonacog alfa to Bioverativ Canada
  • 27 Jun 2017 European Medicines Agency (EMA) approves longer treatment regimen for eftrenonacog alfa in Haemophilia B
  • 24 Mar 2017 Bioverativ has patent protection for eftrenonacog alfa in Japan
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top